Cantor Fitzgerald Estimates Gossamer Bio FY2025 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Gossamer Bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the company will earn ($0.72) per share for the year. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $9.20.

Gossamer Bio Price Performance

Shares of GOSS opened at $0.90 on Wednesday. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.60. The stock has a fifty day moving average price of $0.84 and a 200 day moving average price of $0.91. The company has a market cap of $204.40 million, a P/E ratio of -2.82 and a beta of 1.81.

Institutional Trading of Gossamer Bio

Institutional investors have recently modified their holdings of the company. US Bancorp DE acquired a new stake in shares of Gossamer Bio in the third quarter valued at $39,000. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio in the third quarter valued at $67,000. Algert Global LLC acquired a new stake in shares of Gossamer Bio in the second quarter valued at $75,000. Sequoia Financial Advisors LLC lifted its holdings in shares of Gossamer Bio by 26.7% in the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after buying an additional 25,000 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Gossamer Bio by 67.4% in the second quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock valued at $279,000 after buying an additional 124,913 shares during the period. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.